Arecor Therapeutics PLC Ordinary Shares AREC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AREC is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- GBX 136.50
- Day Range
- GBX 133.00–137.50
- 52-Week Range
- GBX 125.00–280.00
- Bid/Ask
- GBX 133.00 / GBX 140.00
- Market Cap
- GBX 4.21 Bil
- Volume/Avg
- 19,481 / 15,653
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 44
- Website
- https://www.arecor.com
Comparables
Valuation
|
Metric
|
AREC
|
ZURA
|
GHRS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.46 | 2.66 | 2.68 |
Price/Sales | 12.25 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
AREC
ZURA
GHRS
Financial Strength
|
Metric
|
AREC
|
ZURA
|
GHRS
|
|---|---|---|---|
Quick Ratio | 2.22 | 4.92 | 24.14 |
Current Ratio | 2.52 | 4.97 | 24.49 |
Interest Coverage | −383.41 | — | −706.38 |
Quick Ratio
AREC
ZURA
GHRS
Profitability
|
Metric
|
AREC
|
ZURA
|
GHRS
|
|---|---|---|---|
Return on Assets (Normalized) | −45.23% | −71.08% | −12.75% |
Return on Equity (Normalized) | −84.34% | −139.85% | −13.12% |
Return on Invested Capital (Normalized) | −59.86% | −99.89% | −16.87% |
Return on Assets
AREC
ZURA
GHRS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vvhnvjhtsh | Tgd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kwfrcclp | Vsggf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wttmncpyw | Hjmjnw | $97.8 Bil | |
MRNA
| Moderna Inc | Drzfdfmf | Fdpm | $38.8 Bil | |
ARGX
| argenx SE ADR | Nqrqhghp | Jrt | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Hywgczzql | Nnpgt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hlgjbrsg | Xcbspw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lymwqsmv | Sbtppr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jxyhgnvwq | Gpskgh | $12.5 Bil | |
INCY
| Incyte Corp | Jvdgckqxv | Ndlnrn | $11.5 Bil |